Gallium-67 citrate scanning in Hodgkin's disease and non-Hodgkin's lymphoma

Journal Article · Thu Jan 01 04:00:00 EST 1976 · Cancer, v. 37, no. 1, pp. 250-257

DOI:https://doi.org/10.1002/1097-0142(197601)37:1<250::AID-CNCR2820370134>3.0.CO;2-N· OSTI ID:4042525

Horn, N L; Ray, G R; Kriss, J P

Gallium-67 citrate scintigraphy was performed in 33 patients with Hodgkin's disease and 25 patients with non-Hodgkin's lymphoma. Three hundred twenty-eight sites of potential involvement were investigated. Confirmation of involvement was made by physical examination, roentgenographic evaluation and histopathologic examination of tissue obtained at diagnostic laparotomy. The results of scintigraphy correlated with all other clinicopathologic data in only 35 percent of patients, the true-positive rate being significantly higher above the diaphragm (61 percent) than below (40 percent). The overall true-positive and true-negative rates were 53 and 90 percent, respectively. Gallium-67-citrate scintigraphy may be useful as an adjunct to established clinical staging procedures in untreated patients and in the detection of recurrent disease in treated patients. Our data indicate it is not sufficiently reliable to replace established methods presently used for clinical staging. (auth)

• Research Organization: Stanford Univ., CA
• Sponsoring Organization: USDOE
• NSA Number: NSA-33-029947
• OSTI ID: 4042525
• Journal Information: Cancer, v. 37, no. 1, pp. 250-257, Journal Name: Cancer, v. 37, no. 1, pp. 250-257; ISSN CANCA
• Country of Publication: United States
• Language: English

Related Subjects

*HODGKINS DISEASE-- DIAGNOSIS
*LYMPHOMAS-- SCINTISCANNING
*SCINTISCANNING-- GALLIUM 67
*SPLEEN-- SCINTISCANNING
550601* --Biomedical Sciences
Basic Studies--Medicine-- Unsealed Radionuclides in Diagnostics
HISTOLOGY
N48830* --Life Sciences--New Tracer Techniques--Other
PATHOLOGY
PATIENTS
TRACER TECHNIQUES